Last updated: May 24, 2026
Alcaftadine supply is split between (i) active pharmaceutical ingredient (API) and key intermediates producers and (ii) finished-dose manufacturers that fill and package ophthalmic products. Public data that reliably maps specific alcaftadine API and intermediate suppliers to commercial brands is limited; brand-level filings and regulatory dossiers more consistently identify finished-dose manufacturers, while API procurement chains often remain undisclosed.
Who supplies the alcaftadine API for ophthalmic products?
Answer: API supplier identities are often not disclosed publicly in FDA-facing product listings. In practice, due diligence for alcaftadine procurement relies on (1) manufacturer fields in FDA listings (finished dosage), (2) inspections and consent decree disclosures tied to specific facilities, (3) DMF holders’ names in FDA records (when accessible), and (4) commercial sourcing documents in licensing and settlement records.
What supplier identifiers show up most often for alcaftadine?
Commonly observable supplier identifiers for alcaftadine products include:
- Drug product manufacturer and packager for the marketed ophthalmic dosage form (typically “solution”).
- Strength-specific label claims tied to the finished-dose site.
- Contract manufacturing and packaging operations named in regulatory submissions and label sections (when disclosed).
Which companies manufacture finished-dose alcaftadine eye drops (USP strength and dosage form)?
Answer: Finished-dose manufacturers are more frequently identifiable than API suppliers. For alcaftadine, market products are positioned as ophthalmic solutions, with vendor roles split across fill-finish and packaging.
What product-manufacturing roles matter for supply risk?
When assessing alcaftadine supply continuity, the key roles are:
- API to DP conversion: conversion may include sterile solution preparation, filtration, and aseptic processing.
- Sterile fill-finish: bottle/sterile container filling, stoppering, and sealing.
- Primary packaging: carton and labeling that bind to NDC and lot release.
Where does supply information appear in practice?
- FDA product label and “Drug Listing” metadata for the NDC
- Sponsor/labeler information
- Site-specific manufacturing statements on the package insert
What are the procurement pathways for alcaftadine (API vs. finished-dose sourcing)?
Answer: Most ophthalmic supply chains follow one of two procurement pathways:
- DP sourcing (most common): the brand owner contracts a fill-finish and packaging network that handles sterile manufacturing under cGMP and submits product in-market.
- API + DP build: the sponsor buys API and then contracts sterile compounding/fill-finish for the final sterile ophthalmic solution.
Why procurement mapping is harder at the API level
For ophthalmic products like alcaftadine, API supply often sits behind:
- DMF or confidential commercial arrangements
- Multi-site intermediate supply that is not public
- Non-disclosure of custom synthesis arrangements
How do you identify alcaftadine suppliers in FDA and regulatory records?
Answer: The highest-yield approach is cross-referencing multiple FDA sources that contain facility-level and listing-level information for the exact NDC and strength.
Regulatory data points to check for supplier identification
- NDC labeler and manufacturer fields (DP manufacturer)
- DMF-linked facility names (API or intermediate manufacturing sites, when accessible through records)
- Inspection outcomes tied to specific facilities (to infer active supply constraints)
- ANDA/505(b)(2) submissions that cite manufacturing sites for the specific strength and dosage form (where publicly available)
Which alcaftadine brands and strengths drive the supplier map?
Answer: Supplier identification is NDC- and strength-dependent. The supplier roster changes when the market expands across:
- Different strengths
- Different bottle formats
- Different labelers or licensees
Supply mapping by strength
Finished-dose supplier fields must be mapped separately by:
- Strength (for example, 0.005% vs other strengths if marketed)
- Container size and formulation match
- Regional label (US vs non-US)
What manufacturing constraints affect alcaftadine supply continuity?
Answer: Ophthalmic small-molecule supply faces constraints that affect both sterile processing and batch release.
Key technical supply bottlenecks
- Sterile solution manufacturing and aseptic fill-finish capacity
- Filtration performance for ophthalmic solutions
- Container closure integrity testing capacity
- Batch release turnaround time under QMS
Quality and compliance risks that can force supplier substitution
- FDA warning letters or import alerts linked to ocular sterile manufacturing
- Sterility assurance failures
- Deviations tied to filtration, particulate control, or container closure
Which suppliers are likely to be involved beyond the labeler (CMO/packager ecosystem)?
Answer: Even when the label identifies a single “manufacturer,” the supply chain typically uses:
- CMOs for aseptic filling and packaging
- Testing labs for QC release testing
- Primary container vendors that supply elastomer or closure components
What contract manufacturing roles appear in supply disputes
In IP and supply disputes, parties often reference:
- Fill-finish subcontractors
- Contract sterile processing sites
- QC and stability testing subcontractors
What generic entry risks exist for alcaftadine based on supplier concentration?
Answer: Supplier concentration affects timelines for abbreviated pathway entries and scale-up risk. If fill-finish sites are limited, generic and 505(b)(2) entrants may face:
- Delayed validation batches
- Longer bridging study schedules
- Increased risk of supply interruption around launch
How supplier concentration affects Paragraph IV strategy
For alcaftadine, generic entrants typically mitigate launch risk by securing:
- A committed sterile fill-finish site
- A qualified sterility testing and release network
- DP and packaging comparability data
Key takeaways
- Finished-dose alcaftadine ophthalmic suppliers are more identifiable than alcaftadine API suppliers because FDA-facing public records more consistently list DP manufacturer and packager fields.
- API supplier identities and intermediate producers are frequently not disclosed publicly; supplier mapping requires cross-referencing NDC manufacturer fields, DMF-linked facility records (where accessible), and facility-level compliance records.
- For supply risk management, focus on sterile fill-finish capacity, batch release timelines, and site qualification status rather than only brand labeler identity.
FAQs
- How can I identify the fill-finish manufacturer for an alcaftadine NDC?
- Do DMFs for alcaftadine reveal the exact API or intermediate suppliers?
- What sterile manufacturing constraints most often delay ophthalmic solution launches for alcaftadine?
- How does NDC-specific manufacturing affect alcaftadine supply continuity during outages?
- What documentation typically supports API-to-DP comparability when switching alcaftadine suppliers?
References
- FDA. Orange Book and Drug Product listings (accessed via FDA Drugs@FDA and related databases).
- FDA. Drug Master Files (DMF) guidance and DMF-related public record mechanisms.
- FDA. Current Good Manufacturing Practice (cGMP) requirements for sterile ophthalmic drug products.
